文献速递前列腺癌

转移性去势抵抗性前列腺癌患者对卡巴他赛与多西他赛一线化疗的偏好:CABADOC试验

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
PubMed 文献 · Eur Urol · 2021-11-14

CABADOC试验将195例化疗初治的转移性去势抵抗性前列腺癌患者随机分配至多西他赛→卡巴他赛或反向顺序,152例符合改良意向治疗分析。66例(43%)偏好卡巴他赛,40例(27%)偏好多西他赛,46例(30%)无偏好(P=0.004);偏好卡巴他赛主要与疲劳更少(72%)和生活质量更好(64%)相关。

要点

  • 化疗初治mCRPC患者中43%偏好卡巴他赛,27%偏好多西他赛,30%无偏好(P=0.004)。
  • 偏好卡巴他赛的主要原因包括疲劳更少(72%)和生活质量更好(64%)。
  • 更多患者偏好第一治疗阶段(43%,95%CI 36-52%)而非第二治疗阶段(27%,95%CI 20-34%)。

核心结论

  • 在接受两种紫杉烷的化疗初治mCRPC患者中,偏好卡巴他赛的比例显著高于多西他赛。
  • 疲劳更少和生活质量更好是驱动患者选择卡巴他赛的两个主要原因。

研究设计与样本

  • 化疗初治的mCRPC患者按1:1随机接受多西他赛(75 mg/m2,每3周×4周期)后接卡巴他赛(25 mg/m2,每3周×4周期)或相反顺序。
  • 随机化按既往阿比特龙或恩扎卢胺使用分层。
  • 195例随机,152例符合预设的改良意向治疗分析标准。
  • 主要终点为第二紫杉烷后通过专用问卷评估的患者偏好。
  • 次要终点包括偏好原因、PSA反应、影像学无进展生存和总生存。

主要发现

  • 66例(43%)偏好卡巴他赛,40例(27%)偏好多西他赛,46例(30%)无偏好(P=0.004,校正治疗阶段效应)。
  • 更多患者偏好第一治疗阶段(43%,95%CI 36-52%) vs 第二治疗阶段(27%,95%CI 20-34%)。
  • 偏好卡巴他赛主要与疲劳更少(72%)、生活质量更好(64%)及其他不良事件(脱发、疼痛、指甲病变、水肿)相关。
  • 不良事件与每种药物已知的安全性特征一致。

关键数值与推荐

  • 多西他赛给药方案:75 mg/m2,每3周×4周期。
  • 卡巴他赛给药方案:25 mg/m2,每3周×4周期。
  • 主要终点为患者偏好,通过第二紫杉烷后的专用问卷评估。
  • 偏好卡巴他赛的原因中疲劳更少占72%,生活质量更好占64%。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论指出,接受两种紫杉烷的化疗初治mCRPC患者中偏好卡巴他赛的比例显著更高,疲劳更少和生活质量更好是主要驱动原因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficacy but a different safety profile in the first-line mCRPC setting. OBJECTIVE: To assess patient preference between docetaxel and cabazitaxel among men who received one or more doses of each taxane and did not experience progression after the first taxane. DESIGN, SETTING, AND PARTICIPANTS: Chemotherapy-naïve patients with mCRPC were randomized 1:1 to receive docetaxel (75 mg/m2 every 3 wk × 4 cycles) followed by cabazitaxel (25 mg/m2 every 3 wk × 4 cycles) or the reverse sequence. Randomization was stratified by prior abiraterone or enzalutamide use. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was patient preference, assessed via a dedicated questionnaire after the second taxane. Secondary endpoints included reasons for patient preference, prostate-specific antigen response, radiological progression-free survival, and overall survival. This clinical trial is registered at ClinicalTrials.gov as NCT02044354. RESULTS AND LIMITATIONS: Of 195 men randomized, 152 met the prespecified modified intent-to-treat criteria for analysis. Overall, 66 patients (43%) preferred cabazitaxel, 40 (27%) preferred docetaxel, and 46 (30%) had no preference (p = 0.004, adjusted for treatment period effect). More patients preferred treatment period 1 (43%, 95% confidence interval [CI] 36-52%) versus period 2 (27%, 95% CI 20-34%). Patient preference for cabazitaxel was mainly related to less fatigue (72%), better quality of life (64%), and other adverse events (hair loss, pain, nail disorders, edema). Adverse events were consistent with the known safety profile of each drug. CONCLUSIONS: A significantly higher proportion of chemotherapy-naïve men with mCRPC who received both taxanes preferred cabazitaxel over docetaxel. Less fatigue and better quality of life were the two main reasons driving patient choice. PATIENT SUMMARY: Men with metastatic castration-resistant prostate cancer preferred cabazitaxel over docetaxel for chemotherapy, mainly because of less fatigue and better quality of life.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Baciarello G, Delva R, Gravis G, et al. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. Eur Urol. 2021. PMID: 34789394. doi:10.1016/j.eururo.2021.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。